The trial achieved both of those its Principal endpoints, with semaglutide 2.4 mg demonstrating statistically important and exceptional improvements in liver fibrosis with no worsening of steatohepatitis, together with resolution of steatohepatitis without any worsening of liver fibrosis in those wi